Skip to main content

Startup wants to reverse Parkinson’s and Alzheimer’s using human blood extract

A cutting-edge startup is working on a treatment for neurodegenerative diseases such as Parkinson’s and Alzheimer’s by altering the concentration of plasma proteins in patients. This work is based on previous research from Stanford University indicating that cognitive decline in mice can be reversed through injections of blood taken from younger mice.

“Alkahest recently announced the initiation of a Phase 2 trial of its proprietary human plasma fraction, GRF6021, for the treatment of Parkinson’s disease with associated mild cognitive impairment or dementia,” Steven Braithwaite, Chief Scientific Officer at Alkahest, told Digital Trends. “As humans age, there is change in the makeup of the proteins in plasma. Some of the key, function-driving plasma proteins increase or decrease with time. At Alkahest, we have termed these changing proteins ‘chronokines.’”

It is the loss of these beneficial chronokine proteins which are implicated with the onset of various age-related diseases through the reduction of regenerative properties that preserve biological functions. In previous studies, the human plasma fraction, GRF6021, has been shown to enhance neurogenesis, improve learning and memory, slow cognitive decline, reduce inflammation, and preserve cell health in animal models.

In Alkahest’s new trial, 90 Parkinson’s patients, mostly in their 70s and 80s, will receive multiple injections containing GRF6021. This plasma fraction is extracted from blood taken from blood banks, with an average donor age of 32. Over the course of the study, the participants will be tested for signs of improved memory, attention, language skills, and more.

“We believe that GRF6021’s unique properties grants the candidate a potential mechanistic advantage over currently available and clinical-stage therapies, whose mode of action typically targets one symptom of disease — and for the most part are ineffective at addressing the complex root causes of disease and aging,” Braithwaite continued.

After the completion of this trial in 2020, Alkahest next plans to advance GRF6021 into larger Phase 3 trials. The company has also carried out trials involving a second proprietary plasma protein fraction, GRF6019, in Alzheimer’s patients.

“In preclinical trials, both products reversed age and disease-related cognitive decline,” Karoly Nikolich, CEO of Alkahest, told us. “We are currently studying GRF6019 in an ongoing Phase 2 trial in mild to moderate Alzheimer’s disease patients. Based on the promise of what we have observed in earlier preclinical and clinical trials, Alkahest will also be initiating a Phase 2 trial in severe Alzheimer’s patients planned for initiation in the first half of 2019.”

Editors' Recommendations

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
This AI cloned my voice using just three minutes of audio
acapela group voice cloning ad

There's a scene in Mission Impossible 3 that you might recall. In it, our hero Ethan Hunt (Tom Cruise) tackles the movie's villain, holds him at gunpoint, and forces him to read a bizarre series of sentences aloud.

"The pleasure of Busby's company is what I most enjoy," he reluctantly reads. "He put a tack on Miss Yancy's chair, and she called him a horrible boy. At the end of the month, he was flinging two kittens across the width of the room ..."

Read more
Digital Trends’ Top Tech of CES 2023 Awards
Best of CES 2023 Awards Our Top Tech from the Show Feature

Let there be no doubt: CES isn’t just alive in 2023; it’s thriving. Take one glance at the taxi gridlock outside the Las Vegas Convention Center and it’s evident that two quiet COVID years didn’t kill the world’s desire for an overcrowded in-person tech extravaganza -- they just built up a ravenous demand.

From VR to AI, eVTOLs and QD-OLED, the acronyms were flying and fresh technologies populated every corner of the show floor, and even the parking lot. So naturally, we poked, prodded, and tried on everything we could. They weren’t all revolutionary. But they didn’t have to be. We’ve watched enough waves of “game-changing” technologies that never quite arrive to know that sometimes it’s the little tweaks that really count.

Read more
Digital Trends’ Tech For Change CES 2023 Awards
Digital Trends CES 2023 Tech For Change Award Winners Feature

CES is more than just a neon-drenched show-and-tell session for the world’s biggest tech manufacturers. More and more, it’s also a place where companies showcase innovations that could truly make the world a better place — and at CES 2023, this type of tech was on full display. We saw everything from accessibility-minded PS5 controllers to pedal-powered smart desks. But of all the amazing innovations on display this year, these three impressed us the most:

Samsung's Relumino Mode
Across the globe, roughly 300 million people suffer from moderate to severe vision loss, and generally speaking, most TVs don’t take that into account. So in an effort to make television more accessible and enjoyable for those millions of people suffering from impaired vision, Samsung is adding a new picture mode to many of its new TVs.
[CES 2023] Relumino Mode: Innovation for every need | Samsung
Relumino Mode, as it’s called, works by adding a bunch of different visual filters to the picture simultaneously. Outlines of people and objects on screen are highlighted, the contrast and brightness of the overall picture are cranked up, and extra sharpness is applied to everything. The resulting video would likely look strange to people with normal vision, but for folks with low vision, it should look clearer and closer to "normal" than it otherwise would.
Excitingly, since Relumino Mode is ultimately just a clever software trick, this technology could theoretically be pushed out via a software update and installed on millions of existing Samsung TVs -- not just new and recently purchased ones.

Read more